The potential utility of curcumin in the treatment of HER-2-overexpressed breast cancer: An in vitro and in vivo comparison study with herceptin

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Chen, Dar Ren ^a,c   Lai, Hung Wen ^a,b   Chien, Su Yu ^a,c   Kuo, Shou Jen ^a,c   Tseng, Ling Ming ^b,d   Lin, Hui Yi ^e   Chi, Chin Wen ^b  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SIZE; CELL CYCLE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 80053546170     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/486568     Document Type: Article

References (49)

1. Jung S. Y., Han W., Lee J. W., Ko E., Kim E., Yu J. H., Moon H. G., Park I. A., Oh D. Y., Im S. A., Kim T. Y., Hwang K. T., Kim S. W., Noh D. Y., Ki-67 expression gives additional prognostic information on St. Gallen 2007 and adjuvant! online risk categories in early breast cancer Annals of Surgical Oncology 2009 16 5 1112 1121
2. Ludovini V., Gori S., Colozza M., Pistola L., Rulli E., Floriani I., Pacifico E., Tofanetti F. R., Sidoni A., Basurto C., Rull A., Crin L., Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival Annals of Oncology 2008 19 5 883 890 (Pubitemid 351627302)
3. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987 235 4785 177 182 (Pubitemid 17231334)
4. Hudziak R. M., Schlessinger J., Ullrich A., Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells Proceedings of the National Academy of Sciences of the United States of America 1987 84 20 7159 7163
5. Press M. F., Pike M. C., Chazin V. R., Hung G., Udove J. A., Markowicz M., Danyluk J., Godolphin W., Sliwkowski M., Akita R., Paterson M. C., Slamon D. J., Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease Cancer Research 1993 53 20 4960 4970 (Pubitemid 23326194)
6. Seshadri R., Firgaira F. A., Horsfall D. J., McCaul K., Setlur V., Kitchen P., Clinical significance of HER-2/neu oncogene amplification in primary breast cancer Journal of Clinical Oncology 1993 11 10 1936 1942 (Pubitemid 23304619)
7. Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2 The New England Journal of Medicine 2001 344 11 783 792 (Pubitemid 32222155)
8. Pegram M. D., Lipton A., Hayes D. F., Weber B. L., Baselga J. M., Tripathy D., Baly D., Baughman S. A., Twaddell T., Glaspy J. A., Slamon D. J., Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment Journal of Clinical Oncology 1998 16 8 2659 2671 (Pubitemid 28363029)
9. Cobleigh M. A., Vogel C. L., Tripathy D., Robert N. J., Scholl S., Fehrenbacher L., Wolter J. M., Paton V., Shak S., Lieberman G., Slamon D. J., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease Journal of Clinical Oncology 1999 17 9 2639 2648 (Pubitemid 29415219)
10. Piccart-Gebhart M. J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C. H., Steger G., Huang C. S., Andersson M., Inbar M., Lichinitser M., Lng I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T. M., Rschoff J., Sto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M. S., Gelber R. D., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer The New England Journal of Medicine 2005 353 16 1659 1672 (Pubitemid 41464705)
11. Romond E. H., Perez E. A., Bryant J., Suman V. J., Geyer C. E., Davidson N. E., Tan-Chiu E., Martino S., Paik S., Kaufman P. A., Swain S. M., Pisansky T. M., Fehrenbacher L., Kutteh L. A., Vogel V. G., Visscher D. W., Yothers G., Jenkins R. B., Brown A. M., Dakhil S. R., Mamounas E. P., Lingle W. L., Klein P. M., Ingle J. N., Wolmark N., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer The New England Journal of Medicine 2005 353 16 1673 1684 (Pubitemid 41464706)
12. Joensuu H., Kellokumpu-Lehtinen P. L., Bono P., Alanko T., Kataja V., Asola R., Utriainen T., Kokko R., Hemminki A., Tarkkanen M., Turpeenniemi-Hujanen T., Jyrkki S., Flander M., Helle L., Ingalsuo S., Johansson K., Jskelinen A. S., Pajunen M., Rauhala M., Kaleva-Kerola J., Salminen T., Leinonen M., Elomaa I., Isola J., Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer The New England Journal of Medicine 2006 354 8 809 820 (Pubitemid 43290919)
13. Vogel C. L., Cobleigh M. A., Tripathy D., Gutheil J. C., Harris L. N., Fehrenbacher L., Slamon D. J., Murphy M., Novotny W. F., Burchmore M., Shak S., Stewart S. J., Press M., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer Journal of Clinical Oncology 2002 20 3 719 726 (Pubitemid 34111379)
14. Pohlmann P. R., Mayer I. A., Mernaugh R., Resistance to trastuzumab in breast cancer Clinical Cancer Research 2009 15 24 7479 7491
15. Esteva F. J., Valero V., Booser D., Guerra L. T., Murray J. L., Pusztai L., Cristofanilli M., Arun B., Esmaeli B., Fritsche H. A., Sneige N., Smith T. L., Hortobagyi G. N., Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer Journal of Clinical Oncology 2002 20 7 1800 1808 (Pubitemid 34273269)
16. Aggarwal B. B., Kumar A., Bharti A. C., Anticancer potential of curcumin: preclinical and clinical studies Anticancer Research 2003 23 1 A 363 398 (Pubitemid 36361976)
17. Sharma R. A., Gescher A. J., Steward W. P., Curcumin: the story so far European Journal of Cancer 2005 41 13 1955 1968 (Pubitemid 41557681)
18. Chauhan D. P., Chemotherapeutic potential of curcumin for colorectal cancer Current Pharmaceutical Design 2002 8 19 1695 1706 (Pubitemid 34846196)
19. Chen A., Xu J., Johnson A. C., Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1 Oncogene 2006 25 2 278 287 (Pubitemid 43083689)
20. Shao Z. M., Shen Z. Z., Liu C. H., Sartippour M. R., Go V. L., Heber D., Nguyen M., Curcumin exerts multiple suppressive effects on human breast carcinoma cells International Journal of Cancer 2002 98 2 234 240 (Pubitemid 34150808)
21. Korutla L., Cheung J. Y., Mendelsohn J., Kumar R., Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin Carcinogenesis 1995 16 8 1741 1745
22. Dorai T., Gehani N., Katz A., Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein Molecular Urology 2000 4 1 1 6 (Pubitemid 30238682)
23. Hong R. L., Spohn W. H., Hung M. C., Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu1 Clinical Cancer Research 1999 5 7 1884 1891 (Pubitemid 29334473)
24. Hussain A. R., Al-Rasheed M., Manogaran P. S., Al-Hussein K. A., Platanias L. C., Al Kuraya K., Uddin S., Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias Apoptosis 2006 11 2 245 254 (Pubitemid 43291024)
25. Camacho-Barquero L., Villegas I., Snchez-Calvo J. M., Talero E., Snchez-Fidalgo S., Motilva V., Alarcn de la Lastra C., Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis International Immunopharmacology 2007 7 3 333 342 (Pubitemid 46186172)
26. Winn R. J., McClure J. S., NCCN Clinical Practice Guidlines in Oncology: Breast Cancer. 2010, http://www.nccn.org/professionals/physiciangls/PDF/breast. pdf
27. Lin A., Karin M., NF- B in cancer: a marked target Seminars in Cancer Biology 2003 13 2 107 114
28. Biswas D. K., Dai S. C., Cruz A., Weiser B., Graner E., Pardee A. B., The nuclear factor kappa B (NF- B): a potential therapeutic target for estrogen receptor negative breast cancers Proceedings of the National Academy of Sciences of the United States of America 2001 98 18 10386 10391 (Pubitemid 32803029)
29. Nakanishi C., Toi M., Nuclear factor- B inhibitors as sensitizers to anticancer drugs Nature Reviews Cancer 2005 5 4 297 309 (Pubitemid 40488635)
30. Biswas D. K., Iglehart J. D., Linkage between EGFR family receptors and nuclear factor KappaB (NF- B) signaling in breast cancer Journal of Cellular Physiology 2006 209 3 645 652 (Pubitemid 44665682)
31. Aggarwal B. B., Shishodia S., Takada Y., Banerjee S., Newman R. A., Bueso-Ramos C. E., Price J. E., Curcumin suppresses the paclitaxel-induced nuclear factor- B pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice Clinical Cancer Research 2005 11 20 7490 7498 (Pubitemid 41507710)
32. Kamat A. M., Sethi G., Aggarwal B. B., Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor- B and nuclear factor- B-regulated gene products in IFN- -sensitive and IFN- -resistant human bladder cancer cells Molecular Cancer Therapeutics 2007 6 3 1022 1030 (Pubitemid 46554572)
33. Kang H. J., Lee S. H., Price J. E., Kim L. S., Curcumin suppresses the paclitaxel-induced nuclear factor- B in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model Breast Journal 2009 15 3 223 229
34. Normanno N., Campiglio M., Perrone F., De Luca A., Menard S., Is the gefitinib plus trastuzumab combination feasible in breast cancer patients? Annals of Oncology 2005 16 10 1709 (Pubitemid 41510148)
35. Moulder S. L., Arteaga C. L., A phase I/II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpresses HER2/neu (ErbB-2) Clinical Breast Cancer 2003 4 2 142 145 (Pubitemid 36939421)
36. Moulder S. L., Yakes F. M., Muthuswamy S. K., Bianco R., Simpson J. F., Arteaga C. L., Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo Cancer Research 2001 61 24 8887 8895 (Pubitemid 34013905)
37. Xia W., Gerard C. M., Liu L., Baudson N. M., Ory T. L., Spector N. L., Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells Oncogene 2005 24 41 6213 6221 (Pubitemid 43080044)
38. Vichai V., Kirtikara K., Sulforhodamine B colorimetric assay for cytotoxicity screening Nature Protocols 2006 1 3 1112 1116
39. Chou T. C., Talalay P., A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems Journal of Biological Chemistry 1977 252 18 6438 6442 (Pubitemid 8193791)
40. Chou T. C., Talalay P., Harra K. R., TA C., Applications of the median effect principle for the assessment of low dose risk of carcinogenesis and for the quantitation of synergism and antagonism of chemotherapeutic agents in new avenues in development cancer chemotherapy Bristol-Myers Symposium 1987 New York, NY, USA Academic Press 37 64
41. Hanahan D., Weinberg R. A., The hallmarks of cancer Cell 2000 100 1 57 70 (Pubitemid 30046295)
42. Longva K. E., Pedersen N. M., Hasleks C., Stang E., Madshus I. H., Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2 International Journal of Cancer 2005 116 3 359 367 (Pubitemid 40993331)
43. Singh S., Shi Q., Bailey S. T., Palczewski M. J., Pardee A. B., Iglehart J. D., Biswas D. K., Nuclear factor- B activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer Molecular Cancer Therapeutics 2007 6 7 1973 1982 (Pubitemid 47052487)
44. Monks N. R., Biswas D. K., Pardee A. B., Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF- B as a target Journal of Cellular Biochemistry 2004 92 4 646 650 (Pubitemid 44264255)
45. Chen A. L., Hsu C. H., Lin J. K., Hsu M. M., Ho Y. F., She T. S., Ko J. Y., Lin J. T., Lin B. R., Wu M. S., Yu H. S., Jee S. H., Chen G. S., Chen T. M., Chen C. A., Lai M. K., Pu Y. S., Pan M. H., Wang Y. J., Tsai C. C., Hsieh C. Y., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions Anticancer Research 2001 21 4 B 2895 2900
46. Lpez-Lzaro M., Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent Molecular Nutrition and Food Research 2008 52 1 S103 S127
47. Rao C. V., Rivenson A., Simi B., Reddy B. S., Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound Cancer Research 1995 55 2 259 266
48. Soni K. B., Kuttan R., Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers Indian Journal of Physiology and Pharmacology 1992 36 4 273 275 (Pubitemid 23031285)
49. Su C. C., Yang J. S., Lu C. C., Chiang J. H., Wu C. L., Lin J. J., Lai K. C., Hsia T. C., Lu H. F., Fan M. J., Chung J. G., Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model Phytotherapy Research 2010 24 2 189 192